UNSPSC 51311706: Phenyltoloxamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56O4H6ZT2K, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride but more generally known as phenyltoloxamine hydrochloride, which bears US NIH Compound Identifier 22528. Most nations, for tariff and trade purposes, schedule phenyltoloxamine hydrochloride under HS 29221980 and SITC 51461.

As of Q4 2014, PHENYLTOLOXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phenyltoloxamine hydrochloride bears US NLM identifiers UMLS ID C0770856 and NCI Concept Code C97702. SMILES: CN(C)CCOC1CCCCC1CC2CCCCC2.CL.

UNSPSC 51311706 Phenyltoloxamine hydrochloride is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, though recent solicitations tagged to this code show limited direct activity in phenyltoloxamine itself. Instead, state and local governments are sourcing naloxone (an opioid antagonist used in emergency overdose response), generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing agreements and competitive bids. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. The work involves manufacturer pricing submissions, wholesaler-based distribution channels, compliance with FDA and pharmaceutical supply-chain regulations, and fulfillment through authorized distribution networks with quarterly or as-needed delivery schedules.

Geographic activity spans Florida (Seminole County), Texas (Texas Health and Human Services Commission), and Minnesota (MMCAP, which includes Oregon participation). Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with responses due March 26, 2026, requiring manufacturers to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with contract awards effective July 1, 2026.